Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Biodel Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Biodel Inc. - Product Pipeline Review - 2014', provides an overview of the Biodel Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Biodel Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Biodel Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Biodel Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Biodel Inc.'s pipeline products Reasons to buy - Evaluate Biodel Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Biodel Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Biodel Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Biodel Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biodel Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Biodel Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Biodel Inc. Snapshot 5 Biodel Inc. Overview 5 Key Information 5 Key Facts 5 Biodel Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Biodel Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Biodel Inc. - Pipeline Products Glance 11 Biodel Inc. - Late Stage Pipeline Products 11 Filing rejected/Withdrawn Products/Combination Treatment Modalities 11 Biodel Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Biodel Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Biodel Inc. - Drug Profiles 15 Linjeta 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 BIOD-123 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 BIOD-125 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 BIOD-238 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 BIOD-250 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BIOD-531 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 VIAtab 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 BIOD-530 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 glucagon 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 insulin lispro 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Recombinant salmon calcitonin 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 teriparatide 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Biodel Inc. - Pipeline Analysis 30 Biodel Inc. - Pipeline Products by Target 30 Biodel Inc. - Pipeline Products by Route of Administration 31 Biodel Inc. - Pipeline Products by Molecule Type 32 Biodel Inc. - Pipeline Products by Mechanism of Action 33 Biodel Inc. - Recent Pipeline Updates 34 Biodel Inc. - Dormant Projects 38 Biodel Inc. - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 BIOD-105 39 BIOD-107 39 Biodel Inc. - Company Statement 40 Biodel Inc. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables Biodel Inc., Key Information 5 Biodel Inc., Key Facts 5 Biodel Inc. - Pipeline by Indication, 2014 8 Biodel Inc. - Pipeline by Stage of Development, 2014 9 Biodel Inc. - Monotherapy Products in Pipeline, 2014 10 Biodel Inc. - Filing rejected/Withdrawn, 2014 11 Biodel Inc. - Phase II, 2014 12 Biodel Inc. - Phase I, 2014 13 Biodel Inc. - Preclinical, 2014 14 Biodel Inc. - Pipeline by Target, 2014 30 Biodel Inc. - Pipeline by Route of Administration, 2014 31 Biodel Inc. - Pipeline by Molecule Type, 2014 32 Biodel Inc. - Pipeline Products by Mechanism of Action, 2014 33 Biodel Inc. - Recent Pipeline Updates, 2014 34 Biodel Inc. - Dormant Developmental Projects,2014 38 Biodel Inc. - Discontinued Pipeline Products, 2014 39 Biodel Inc., Other Locations 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.